30 Day Trial

ORTHOKNOW content is posted to these pages in real time.

Monthly compilations are available in PDF form.

Quarterly Review

4Q12 and 2012 Revenue: Globus Medical

$386.0MM, +16% (U.S. $355.6MM, +14%; ex-U.S. $30.4MM, +49%)

  • Fusion $238.7MM, +6%
  • Disruptive Technology $147.3MM, +38%

4Q12 revenue: $100.5MM, +14% (U.S. $91.9MM, +13%; ex-U.S. $8.6MM, +37%)

  • Fusion $58.2MM, +3%
  • Disruptive Technology $42.4MM, +35%


  • Pricing staying in mid-single-digits, payer pushback not getting any worse, PODs 10-15% of the market
  • Expanded ex-U.S. footprint to 24 countries with combination of exclusive direct sales and exclusive distributor network
  • Key product launches include Secure-C, AFFIRM Kyphoplasty (1st Algea Therapies product), RISE expandable lumbar fusion device inserted via endoscopic tube, SI-LOK sacroiliac fusion system, FORTIFY expandable titanium/PEEK corpectomy spacer, etc.